Text Size
21 studies found for:    prostate cancer, psma, treat

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells;   Drug: cyclophosphamide
2 Active, not recruiting PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Intervention: Biological: Peptide Vaccine
3 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
4 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
5 Withdrawn Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Condition: Prostate Cancer
Intervention: Drug: Dendritic cell immunotherapy
6 Active, not recruiting Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
7 Not yet recruiting Imaging of Residual Tumor During Prostatectomy
Conditions: Prostate Cancer;   Prostatectomy
Intervention:
8 Unknown † Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: therapeutic autologous dendritic cells
9 Not yet recruiting Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer.
Intervention: Drug: G-202
10 Unknown † GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Condition: Prostate Cancer
Intervention: Biological: GM-CSF gene transduced allogeneic vaccine GVAX
11 Terminated Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: GVAX and ipilimumab
12 Active, not recruiting Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
13 Recruiting A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
14 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
15 Unknown † Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: 177Lu-J591
16 Active, not recruiting Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
Condition: Prostate Cancer
Intervention: Drug: 99mTc-MIP-1404
17 Recruiting Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591
18 Active, not recruiting Vaccine Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine;   Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine
19 Completed Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Conditions: Ovarian;   Melanoma;   Renal;   Prostate;   Colorectal;   Endometrial Carcinoma;   Cervical Carcinoma;   Testicular Cancer;   Thyroid Cancer;   Small Cell Lung Carcinoma;   Mesothelioma;   Breast Carcinoma;   Esophageal Carcinoma;   Gastric Cancer;   Pancreatic Carcinoma;   Neuroendocrine Cancer;   Liver Cancer;   Gallbladder Cancer;   Biliary Tract Cancer;   Anal Carcinoma;   Bone Sarcomas;   Soft Tissue Sarcomas;   Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
20 Not yet recruiting BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Conditions: GBM;   Glioblastoma Multiforme;   Gliosarcoma
Intervention: Drug: PSMA ADC
To Top

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
† Indicates status has not been verified in more than two years